TEVA PHARMACEUTICAL INDUSTRIES LTD·4

Mar 5, 4:11 PM ET

Weiss Amir 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 5, 2026

Insider Transaction Report

Form 4
Period: 2026-03-03
Weiss Amir
Chief Accounting Officer
Transactions
  • Exercise/Conversion

    Ordinary Shares

    [F1][F2]
    2026-03-03+5,17910,829 total
  • Exercise/Conversion

    Restricted Share Units

    [F2][F3][F1]
    2026-03-035,1795,180 total
    Ordinary Shares (5,179 underlying)
Footnotes (3)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • [F3]Restricted share units were granted on March 3, 2023, with 5,179 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027.
Signature
/s/ Dov Bergwerk as attorney-in-fact for Amir Weiss|2026-03-05

Documents

1 file
  • 4
    ownership.xmlPrimary

    4